Geron has not specified what triggers the milestones or their specific amounts per trigger, however it would make sense that getting "orphan drug status" would be a trigger, as will start of the next clinical.
Cramer knows so little about so much. Xoma and Servier scientist have a good handle on drug efficacy and the science. Also the fact FDA granted Orphan drug status to Xoma 358 as a plus to XOMA's efforts is worth mentioning
Just added 28000 at $1.32 too low to pass. CVac is a winner vaccine against cancer, especially ovarian cancer, but much more as well. Find it hard to imagine the type of person that would work to destroy a company engaged in saving lives through cancer research.
With the Phase 3 clinical & good indications a partner is the very least that could be in the works. SInce MEI has do debt, low float, low price, pipeline and drug going into phase 3 and $65 + million in cash a takeover has to be considered. Because Pracinostat in combination with Azacitidine provides high rate and rapid onset of remission of AML patients, it makes me thinks a company familiar is most likely.
Will have to stay tuned in to see how this plays out. I have invested accordingly in MEIP
If the press release needs to be explained to someone that is convinced it is a bad report, they don't understand what the report says. When the abstract details are released they will not have their mind changed because they can't see anything other than their perception or their interpretation right or wrong.
Probably the real reason is it doesn't fit their narrative so therefore they maintain their position regardless.